Skip to main content

Table 2 Characteristics of new oral anticoagulants compared with warfarin

From: Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

Agent Main action Half-life (h) Renal clearance (%) Cross placenta Dose Interactions
Rivaroxaban Anti-factor Xa 6-10 66 + Once daily CYP3A4 inhibitors
Apixaban Anti-factor Xa 10-15 30 + Twice daily CYP3A4 inhibitors
Dabigatran Anti-factor IIa 12-14 80 + Twice daily PPIs
Warfarin Synthesis of vitamin K-dependent factors 36-50   + Adjusted by INR, once daily Multiple with food and drugs
  1. PPIs, proton pump inhibitors. Quinidine is contraindicated for patients on dabigatran. Amiodarone or rifampicin require caution.